Enrique Diaz (@aediazmd) 's Twitter Profile
Enrique Diaz

@aediazmd

UT Health San Antonio - Mays Cancer Center. Hematologist-Oncologist with focus on Lymphomas and Health Care Disparities. Views are my own

ID: 1139343390926135301

calendar_today14-06-2019 01:26:47

224 Tweet

155 Takipçi

198 Takip Edilen

UT Health San Antonio MD Anderson (@uthealthsamda) 's Twitter Profile Photo

Hispanics are often diagnosed at a young age with blood cancer and tend to have worse outcomes than other racial or ethnic groups. Hematologist-oncologists Enrique Diaz, MD, MS, and Gerardo Rosas, MD, explain these health disparities. Learn more: bit.ly/3mqC4Wg

Snegha Ananth (@sneghaananth) 's Twitter Profile Photo

My first month as an attending at UNMC Heme Onc has been an incredible experience, thanks to an amazing and welcoming team! Grateful to work alongside Julie Vose and everyone here (including the photobombers 😉)—Light The Night by The Leukemia & Lymphoma Society

My first month as an attending at <a href="/UNMCHemeOnc/">UNMC Heme Onc</a> has been an incredible experience, thanks to an amazing and welcoming team! Grateful to work alongside <a href="/DrJulieVose/">Julie Vose</a> and everyone here (including the photobombers 😉)—<a href="/LightTheNight/">Light The Night</a> by <a href="/LLSusa/">The Leukemia & Lymphoma Society</a>
Enrique Diaz (@aediazmd) 's Twitter Profile Photo

First-Line Combination of R-CHOP with the PDE4 Inhibitor Roflumilast for High-Risk DLBCL mdpi.com/3046102 #mdpicancers via Cancers MDPI Bench to bedside, a beautiful and highly rewarding journey @UTHealthSAMDA UT Health San Antonio Research The Leukemia & Lymphoma Society GELL_LATAM MDPI

Naveen Pemmaraju, MD (@doctorpemm) 's Twitter Profile Photo

👉FYI: ASCO election is now online! Please consider voting 🗳️ for Dr Jason Westin, MD FACP FASCO ! He is a world renowned physician-researcher in our heme/onc field, and Jason is a fierce advocate for our patients!! #lymsm #Leadership | Naveen Pemmaraju, MD Mike Thompson, MD, PhD, FASCO society.asco.org/about-asco/asc…

👉FYI:  <a href="/ASCO/">ASCO</a> election is now online! Please consider voting 🗳️ for Dr <a href="/Lymphoma_Doc/">Jason Westin, MD FACP FASCO</a> ! He is a world renowned physician-researcher in our heme/onc field, and Jason is a fierce advocate for our patients!! #lymsm #Leadership | <a href="/doctorpemm/">Naveen Pemmaraju, MD</a> <a href="/mtmdphd/">Mike Thompson, MD, PhD, FASCO</a> 

society.asco.org/about-asco/asc…
Michael Wang, MD (@michaelwangmd) 's Twitter Profile Photo

At MD Anderson we are moving beyond chemotherapy, we have proven Acalabrutinib-R is an effective regimen. We are testing Pirtobrunitib-R and Pirtobrutinib-Venetoclax-R for older patients with new mantle cell lymphoma in clinical trials!

At MD Anderson we are moving beyond chemotherapy, we have proven Acalabrutinib-R is an effective regimen. We are testing Pirtobrunitib-R and Pirtobrutinib-Venetoclax-R for older patients with new mantle cell lymphoma in clinical trials!
Sukeshi Arora MD (@drsukeshiarora) 's Twitter Profile Photo

Mark your calendars for Oct 9-10 for San Antonio Liver Cancer Symposium. We are planning a great agenda! Abstract submissions are open now!

Guilherme Perini, MD (@guiperinimd) 's Twitter Profile Photo

My (polemic) take: Watch and wait is dead. Its a pretty clear beneficial trade-off Rituximab for 2 years for >10y without chemo. thelancet.com/journals/lanha…

Michael Wang, MD (@michaelwangmd) 's Twitter Profile Photo

Results from our Phase III ECHO trial of acalabrutinib + BR vs placebo + BR in untreated MCL patients ≥ 65-y.o. showed PFS was substantially improved in the acalabrutinib arm (66.4 vs 49.6 mo., p = 0.016). Toxicity in both arms was manageable. tinyurl.com/ECHO-ABR

Results from our Phase III ECHO trial of acalabrutinib + BR vs placebo + BR in untreated MCL patients ≥ 65-y.o. showed PFS was substantially improved in the acalabrutinib arm (66.4 vs 49.6 mo., p = 0.016). Toxicity in both arms was manageable. tinyurl.com/ECHO-ABR
Enrique Diaz (@aediazmd) 's Twitter Profile Photo

From COO to Genetic Subtypes, and now Lymphoma Microenvironment Archetypes (LymphoMAPs) in DLBCL. #icml2025 Such an heterogeneous disease for which newest therapies are a must Mays Cancer Center at UT Health San Antonio clinicaltrials.gov/study/NCT06977….

From COO to Genetic Subtypes, and now Lymphoma Microenvironment Archetypes (LymphoMAPs) in DLBCL. #icml2025  Such an heterogeneous disease for which newest therapies are a must <a href="/mayscancer/">Mays Cancer Center at UT Health San Antonio</a> clinicaltrials.gov/study/NCT06977….
Enrique Diaz (@aediazmd) 's Twitter Profile Photo

Pretty pleased #icml2025 hearing Mark Roschewski re importance of thinking outside the box. More to come Mays Cancer Center at UT Health San Antonio with our upcoming CT for treatment naive DLBCL. clinicaltrials.gov/study/NCT06977…

Pretty pleased #icml2025 hearing <a href="/RoschewskiMD/">Mark Roschewski</a>
re importance of thinking outside the box.  More to come <a href="/mayscancer/">Mays Cancer Center at UT Health San Antonio</a> with our upcoming CT for treatment naive DLBCL. clinicaltrials.gov/study/NCT06977…
Diva (@diva_baggio) 's Twitter Profile Photo

Promising early data from LOTIS7 presented by Juan P. Alderuccio #18icml highlighting synergy of this BSpAb+ADC combination. Inclusive eligibility criteria (prior ASCT, CART allowed, proof of CD19/20 status not required). Looking forward to more data.

Promising early data from LOTIS7 presented by <a href="/JuanAlderuccio/">Juan P. Alderuccio</a> #18icml highlighting synergy of this BSpAb+ADC combination. Inclusive eligibility criteria (prior ASCT, CART allowed, proof of CD19/20 status not required). Looking forward to more data.
LARVOL (@larvol) 's Twitter Profile Photo

Here are the top 10 trials from the 18th International Conference on Malignant Lymphoma (International Conference on Malignant Lymphoma 2025). Explore data and insights #ICML2025: t.ly/dz8T1 #LARVOL #Hematology #Lymphoma #CancerResearch #Oncology #CancerData #OncologyInsights #18ICML | Graham Collins |

Here are the top 10 trials from the 18th International Conference on Malignant Lymphoma (<a href="/icmlugano/">International Conference on Malignant Lymphoma</a> 2025).

Explore data and insights #ICML2025: t.ly/dz8T1
#LARVOL #Hematology #Lymphoma #CancerResearch #Oncology #CancerData #OncologyInsights #18ICML | <a href="/graham74GC/">Graham Collins</a> |